Separate terms with OR to return results that match either term.
 
Clear All
9,752 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Descending) Package Effective Date Package Discontinuation Date Status
00069-0154-01 00069-0154 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Dec. 14, 2011 Dec. 31, 2017 No Longer Used
00069-0155-01 00069-0155 Cytarabine Cytarabine 2.0 g/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous Jan. 31, 2012 Dec. 31, 2017 No Longer Used
00591-2897-49 00591-2897 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sept. 22, 2016 April 30, 2019 No Longer Used
16714-0777-01 16714-0777 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous May 4, 2018 June 10, 2020 In Use
50242-0245-01 50242-0245 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous June 29, 2020 In Use
50242-0245-86 50242-0245 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous May 3, 2021 In Use
50242-0260-01 50242-0260 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous June 29, 2020 In Use
50242-0260-86 50242-0260 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous May 3, 2021 In Use
63759-0003-01 63759-0003 azacitidine for Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Dec. 5, 2016 In Use
67457-0454-50 67457-0454 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Dec. 14, 2011 Dec. 31, 2021 No Longer Used
67457-0615-20 67457-0615 Cytarabine Cytarabine 2.0 g/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous Jan. 31, 2012 Feb. 1, 2012 No Longer Used
69097-0805-40 69097-0805 Azacitidine Azacitidine For 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 26, 2019 In Use
71288-0108-06 71288-0108 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous June 26, 2020 In Use
00703-3321-01 00703-3321 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Nov. 14, 2005 In Use
00703-3321-04 00703-3321 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Nov. 14, 2005 In Use
00703-3321-91 00703-3321 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Jan. 28, 2008 Oct. 31, 2011 In Use
00703-3321-94 00703-3321 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Jan. 28, 2008 Oct. 31, 2011 In Use
15054-0060-01 15054-0060 Lanreotide acetate Somatuline Depot 60.0 mg/.2mL Hormonal Therapy Somatostatin Analog Subcutaneous Nov. 14, 2007 Aug. 31, 2016 No Longer Used
15054-0090-01 15054-0090 Lanreotide acetate Somatuline Depot 90.0 mg/.3mL Hormonal Therapy Somatostatin Analog Subcutaneous Nov. 14, 2007 Aug. 31, 2016 No Longer Used
15054-0120-01 15054-0120 Lanreotide acetate Somatuline Depot 120.0 mg/.5mL Hormonal Therapy Somatostatin Analog Subcutaneous Nov. 14, 2007 Aug. 31, 2016 No Longer Used
41616-0936-40 41616-0936 Leuprolide Acetate Leuprolide Acetate Hormonal Therapy GnRH Agonist Subcutaneous Dec. 15, 2014 Aug. 31, 2015 No Longer Used
00641-6174-01 00641-6174 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 4, 2005 In Use
00641-6174-10 00641-6174 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 4, 2005 In Use
00641-6175-01 00641-6175 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 4, 2005 In Use
00641-6175-10 00641-6175 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 4, 2005 In Use
00641-6176-01 00641-6176 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 4, 2005 In Use
00641-6176-10 00641-6176 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 4, 2005 In Use
00703-3301-01 00703-3301 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Nov. 14, 2005 In Use
00703-3301-04 00703-3301 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Nov. 14, 2005 In Use
00703-3311-01 00703-3311 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Nov. 14, 2005 In Use
00703-3311-04 00703-3311 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Nov. 14, 2005 In Use
62935-0452-45 62935-0452 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous Jan. 23, 2002 April 26, 2019 No Longer Used
63323-0365-01 63323-0365 OCTREOTIDE ACETATE Octreotide 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 June 30, 2017 No Longer Used
63323-0365-04 63323-0365 OCTREOTIDE ACETATE Octreotide 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 June 30, 2017 No Longer Used
70720-0950-36 70720-0950 Goserelin ZOLADEX 3.6 mg/1 Hormonal Therapy GnRH Agonist Subcutaneous March 31, 2018 In Use
70720-0951-30 70720-0951 Goserelin ZOLADEX 10.8 mg/1 Hormonal Therapy GnRH Agonist Subcutaneous Jan. 26, 2018 In Use
00024-5843-01 00024-5843 Sargramostim Leukine 250.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Nov. 5, 2013 Dec. 30, 2021 No Longer Used
00024-5843-05 00024-5843 Sargramostim Leukine 250.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous May 1, 1991 Dec. 30, 2021 No Longer Used
00024-5844-01 00024-5844 Sargramostim Leukine 500.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Dec. 1, 1996 Dec. 30, 2021 No Longer Used
00024-5844-05 00024-5844 Sargramostim Leukine 500.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Dec. 1, 1996 Dec. 30, 2021 No Longer Used
68001-0527-54 68001-0527 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Feb. 15, 2022 In Use
70121-1237-01 70121-1237 AZACITIDINE AZACITIDINE 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Feb. 9, 2022 In Use
47426-0101-01 47426-0101 Granisetron Sustol 10.0 mg/.4mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Subcutaneous Aug. 9, 2016 Aug. 9, 2016 In Use
47426-0101-06 47426-0101 Granisetron Sustol 10.0 mg/.4mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Subcutaneous Aug. 9, 2016 In Use
50242-0108-01 50242-0108 Rituximab and hyaluronidase Rituxan Hycela 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Subcutaneous June 22, 2017 In Use
50242-0108-86 50242-0108 Rituximab and hyaluronidase Rituxan Hycela 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Subcutaneous June 23, 2017 In Use
55513-0002-01 55513-0002 Darbepoetin alfa Aranesp 25.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sept. 11, 2006 In Use
55513-0002-04 55513-0002 Darbepoetin alfa Aranesp 25.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sept. 11, 2006 In Use
55513-0003-01 55513-0003 Darbepoetin alfa Aranesp 40.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sept. 11, 2006 In Use
55513-0003-04 55513-0003 Darbepoetin alfa Aranesp 40.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sept. 11, 2006 In Use

Found 9,752 results in 6 milliseconds — Export these results